Abstract: In order to achieve high product quality and process reliability in a process for manufacturing an endless profile strand of soft plastic and/or rubber material fed to a supply storage for a sealing profile, edge protection profile or the like on a motor vehicle, it is provided that the manufacturing process be divided into two process sections which are carried out on two manufacturing lines that can be operated independently of one another.

Abstract: The present invention relates to fusion proteins which are capable of binding to phosphatidylserine comprising a phosphatidylserene binding ligand and a modified O6-alkylguanine-DNA alkyltransferase which is capable of autoconjugation to an O6-benzylguanine-modified label, the fusion proteins being capable of binding to phosphatidylserine on the surface of a cell undergoing apoptosis. The invention also relates to recombinant polypeptide precursors of the fusion proteins which comprise a secretion leader sequence, purification tag, protease cleavage site and the fusion protein. Also included in the scope of the invention are nucleic acids encoding the recombinant polypeptide precursor, vectors comprising the nucleic acids, host cells comprising the vectors, methods of production of the fusion proteins, kits and assays for detecting apoptosis.

Abstract: In order to achieve high product quality and process reliability in a process for manufacturing an endless profile strand of soft plastic and/or rubber material fed to a supply storage for a sealing profile, edge protection profile or the like on a motor vehicle, it is provided that the manufacturing process be divided into two process sections which are carried out on two manufacturing lines that can be operated independently of one another.

Abstract: The technology provided herein generally relates to novel specific photoimmuno-theranostics for the use in detection and elimination of skin cancer cells. The technology also relates to novel methods which generate homogeneous and specific photoimmuno-theranostics reagents in a simple, controlled and efficient way. This method combines molecular optical imaging, photodynamic therapy and immunotherapy using SNAP-tag technology.

Abstract: The present invention relates to fusion proteins which are capable of binding to phosphatidylserine comprising a phosphatidylserene binding ligand and a modified O6-alkylguanine-DNA alkyltransferase which is capable of autoconjugation to an O6-benzylguanine-modified label, the fusion proteins being capable of binding to phosphatidylserine on the surface of a cell undergoing apoptosis. The invention also relates to recombinant polypeptide precursors of the fusion proteins which comprise a secretion leader sequence, purification tag, protease cleavage site and the fusion protein. Also included in the scope of the invention are nucleic acids encoding the recombinant polypeptide precursor, vectors comprising the nucleic acids, host cells comprising the vectors, methods of production of the fusion proteins, kits and assays for detecting apoptosis.

Abstract: The application relates to a valve for a line system, comprising a valve body which forms a valve seat, a line system with a supply line for supplying a fluid to the valve seat and with a discharge line for discharging the fluid from the valve seat, which fluid is under a supply pressure in the supply line and under a working pressure in the discharge line, a closing element which interacts with the valve seat for opening and closing the line system, which closing element releases a throttle cross section between the valve seat and the closing element, a restoring element which applies a restoring force on the closing element, which restoring force presses the closing element against the valve seat in order to close the line system, and a pressure chamber in which the fluid is under a closing pressure to close the line system.

Abstract: Complexes suitable for targeting and killing a human target cell comprising a first polypeptide with a binding structure for binding the complex to the cellular surface receptor CD89 (e.g. with an anti CD89 antibody) presented on the cell surface of the human target cell and a second polypeptide comprising a toxic effector domain, preferably Pseudomonas exotoxin A); to nucleic acid molecules encoding said complexes, vectors, host cells containing the nucleic acids and methods for preparation and producing such complexes; compositions and methods for using said complexes for the treatment of diseases, in particular of cancer diseases like leukemia.

Abstract: The technology provided herein relates to novel human antibodies against Plasmodium parasites, in particular against the malaria parasite Plasmodium falciparum. The present disclosure pertains to antibodies against apical membrane antigen 1 (AMA-1). These antibodies have high affinity e.g. to Plasmodium falciparum schizonts and merozoites, inhibit the reinvasion of merozoites into erythrocytes and thereby neutralize parasitic multiplication.

Abstract: The technology provided herein relates to novel anti-parasitic complexes, in particular recombinant fusion proteins suitable as human and/or animal drugs against a parasite of the phylum Apicomplexa, in particular against Plasmodium falciparum (P. falciparum) comprising at least one component A and at least one component B, characterized in that component A has a binding activity for cellular surface structures presented on the surface of a parasite of the phylum Apicomplexa or for parasitic antigens presented on a parasitized host cell, and component B is a compound having anti-parasitic activity.

Abstract: The application relates to a valve for a line system, comprising a valve body which forms a valve seat, a line system with a supply line for supplying a fluid to the valve seat and with a discharge line for discharging the fluid from the valve seat, which fluid is under a supply pressure in the supply line and under a working pressure in the discharge line, a closing element which interacts with the valve seat for opening and closing the line system, which closing element releases a throttle cross section between the valve seat and the closing element, a restoring element which applies a restoring force on the closing element, which restoring force presses the closing element against the valve seat in order to close the line system, and a pressure chamber in which the fluid is under a closing pressure to close the line system.

Abstract: A valve for closing and opening a line system, comprising a valve body which forms a valve seat; a line system with a supply line for supplying a fluid to the valve seat and with a discharge line for discharging the fluid from the valve seat, wherein the fluid is under a supply pressure in the supply line and under a working pressure in the discharge line; a closing element that releases a throttle cross-section between the valve seat and the closing element; a restoring element which applies a restoring force to the closing element; and a pressure chamber in which the fluid is under a closing pressure with which the fluid applies a closing force to the closing element to close the line system.

Abstract: The technology provided herein relates to novel human cytolytic fusion proteins (hCFPs) suitable to induce apoptosis in human cells comprising a target cell-specific binding component and a human effector domain, wherein the binding component comprises an antibody or an antibody fragment with an antigen-binding site for binding to the cellular surface receptor CD64 and the effector domain comprises a variant of wild type human angiogenin (Ang) or a functional fragment thereof; to nucleic acid molecules encoding said recombinant hCFPs, vectors and host cells containing said nucleic acids and methods for preparation and producing these hCFPs.

Abstract: The technology provided herein generally relates to novel specific photoimmuno-theranostics for the use in detection and elimination of skin cancer cells. The technology also relates to novel methods which generate homogeneous and specific photoimmuno-theranostics reagents in a simple, controlled and efficient way. This method combines molecular optical imaging, photodynamic therapy and immunotherapy using SNAP-tag technology.

Abstract: A polypeptide which binds to the surface of AML blast cells and is internalized upon binding to the AML blast cells.

Abstract: The invention is a volume control valve for controlling and metering a fluid in a motor vehicle, comprising a tappet with an actuating end and a free end, said tappet being received in a bearing bush and mounted along its actuating axis so as to be movable back and forth, and a seat valve which is connected to a fluid channel and arranged relative to the tappet in such a way that the free end of the tappet can engage in the valve seat and close the fluid channel when it is engaged in said valve seat, and further comprising a pressure spring which is arranged along the longitudinal axis of the tappet. According to the invention, a welded plate is fastened and/or welded and/or formed on the tappet with the pressure spring arranged thereon, which is supported on the welded plate and the bearing bush.

Abstract: The technology provided herein relates to novel immunoproteases suitable to induce apotosis in selected diseased target cells, comprising the serine protease granzyme M, and methods for using such cytolytic fusion proteins for the treatment of various diseases, in particular for the treatment of cancer.

Abstract: The technology provided herein relates to novel human antibodies against Plasmodium parasites, in particular against the malaria parasite Plasmodium falciparum. The present disclosure pertains to antibodies against apical membrane antigen 1 (AMA-1). These antibodies have high affinity e.g. to Plasmodium falciparum schizonts and merozoites, inhibit the reinvasion of merozoites into erythrocytes and thereby neutralize parasitic multiplication.

Abstract: Complexes suitable for targeting and killing a human target cell comprising a first polypeptide with a binding structure for binding the complex to the cellular surface receptor CD89 (e.g. with an anti CD89 antibody) presented on the cell surface of the human target cell and a second polypeptide comprising a toxic effector domain, preferably Pseudomonas exotoxin A); to nucleic acid molecules encoding said complexes, vectors, host cells containing the nucleic acids and methods for preparation and producing such complexes; compositions and methods for using said complexes for the treatment of diseases, in particular of cancer diseases like leukemia.

Abstract: A compound comprising a photosensitizer covalently coupled to a protein selected from the group consisting of antibodies or their derivatives or fragments thereof, synthetic peptides such as scFv, mimotopes which bind CD antigens, cytokine receptors, interleukin receptors, hormone receptors, growth factor receptors, more particularly tyrosine kinase growth factor receptor of the ErbB family, wherein the photosensitizer is coupled to the binding protein via O6-alkylguanine-DNA alkyltransferase (hAGTm), a modified human DNA repair protein.

Abstract: An immunotoxin for use in the treatment of leishmaniasis A wherein the immunotoxin comprises a portion which is specifically binding to the cellular surface receptor CD64 as a component A and a cell killing portion as a component B, wherein the cell killing portion alters the function, gene expression, or viability of a cell thereby killing Leishmania-infected macrophages and by this eliminates Leishmania.